MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer, following treatment with the company’s allogeneic iNKT cell therapy, agent-797.
The publication titled Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor, presents a patient case from MiNK’s clinical trial NCT05108623. The patient experienced complete remission after failure on platinum-based chemotherapy, autologous stem cell transplant, and multiple ICIs—anti–PD-1, anti–CTLA-4, and anti–TIGIT.
Dr. Benjamin Garmezy, assistant director of genitourinary research for Sarah Cannon Research Institute at SCRI Oncology Partners, commented, “This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers. We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.”
